Dako, a world-leading provider of cancer diagnostic solutions such as pharmDx™, has entered into a collaboration with Bristol-Myers Squibb Company to develop pharmacodiagnostic tests intended to identify patients more likely to benefit from treatment with certain investigational cancer drug candidates under development by Bristol-Myers Squibb.
Dako enters into collaboration with Bristol-Myers Squibb for pharmacodiagnostics